Standing Order
All companies

Biotech

Eli Lilly and Company

LLYNYSEdiversified
Market cap$1.2T
Conviction5/ 5
HQIndianapolis, IN
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$1,347.11

+80.3%

Thesis

Eli Lilly markets the tirzepatide products Mounjaro and Zepbound, which target type 2 diabetes and obesity. As a diversified pharmaceutical company, it also advances an oral GLP-1 pipeline alongside its injectable franchise.

Catalysts

  • Oral GLP-1 candidate clinical readouts
  • Manufacturing capacity expansion for tirzepatide
  • Label expansions for Mounjaro and Zepbound

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07881458 of EloraTZP in adults with obesity/overweight and type 2 diabetes begins recruiting.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07881432 initiated for EloraTZP in obesity without Type 2 diabetes; status NOT_YET_RECRUITING.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07900633 of Eloralintide (LY3841136) initiated in obesity/overweight, T2D and CV risk; status NOT_YET_RECRUITING

  • Nov 12
    OtherClinicalTrials.gov

    Phase 3 trial NCT05556512 of tirzepatide for morbidity/mortality reduction in obesity updated to ACTIVE_NOT_RECRUITING on 2026-11-12.

  • Nov 9
    Trial readoutClinicalTrials.gov

    Phase 2 trial NCT05936151 of Retatrutide on renal function in overweight/obese CKD patients completed.

  • Nov 5
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 3 trial of orforglipron (LY3502970) vs dulaglutide in pediatric Type 2 diabetes (NCT07668336, recruiting)

  • Nov 5
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07794579 of orforglipron initiated in overweight participants at risk of obesity complications.

  • Nov 4
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 3 trial (NCT07369011) of Eloralintide (LY3841136) in obstructive sleep apnea with obesity or overweight; status recruiting.

Not financial advice — research and opinion only. Disclosures